Partnering

Interested in licensing our programs or proprietary technology?

With multiple partner-ready programs and a proprietary ELP technology for modulating pharmacokinetics, PhaseBio has numerous opportunities for licensing. Review the selection below, and contact our Business Development Team to learn more.

Elastin-like Polypeptide (ELP) Technology and Programs Available for License

PhaseBio currently has multiple programs available for license. In addition our ELP platform which is available to partners that could benefit from a sustained release mechanism for their proteins and peptides of interest.

ELASTIN-LIKE POLYPEPTIDE (ELP) TECHNOLOGY

Summary: PhaseBio’s proprietary technology platform for modulating pharmacokinetics has extensive clinical and pre-clinical experience. ELP is based on a naturally-occurring amino acid sequence, can be optimized for desired drug exposure and has broad utility across a wide-range of drug classes and therapeutic areas. ELP technology extends the circulating half-life of proteins and peptides and also provides a sustained-release mechanism, resulting in exposure of active molecules for periods of a week or longer from a single subcutaneous injection. Favorable safety-and-tolerability profile has been well-characterized in multiple clinical trials.

Pemziviptadil – AN ANALOGUE OF VASOACTIVE INTESTINAL PEPTIDE (VIP)

Summary: Once-weekly treatment for Pulmonary Arterial Hypertension (PAH). Pemziviptadil is a subcutaneously-injected, sustained release analogue of the native human peptide vasoactive intestinal peptide (VIP) fused to our ELP biopolymer. VIP is a neurohormone that has vasodilatory, anti-inflammatory and anti-fibrotic activity, as well as positive effects on cardiac function. A Phase 2B trial is ongoing for Pulmonary Arterial Hypertension (PAH).

GLP-2-ELP

Summary: Once-weekly ELP product candidate for short bowel syndrome. A weekly GLP-2 (teduglutide genetically fused to ELP) could significantly improve patient acceptability and adherence for patients with short bowel syndrome. Preclinical data with GLP-2-ELP demonstrated a significantly greater effect on the small intestine in normal rats than with teduglutide.

C-TYPE NATRIURETIC PEPTIDE

Summary: CNP-ELP once weekly product candidate for achondroplasia. A weekly CNP could significantly improve patient adherence compared to a daily injection, leading to improved outcomes. Pre-clinical data with CNP-ELP demonstrated a robust effect on linear growth in mice.

GLP-1 Receptor Antagonist

Summary: Once weekly product candidate for hypoglycemia associated with hyperinsulinemia. Potential treatment for hypoglycemia associated with hyperinsulinemia; congenital hyperinsulinism or hyperinsulinemic hypoglycemia post bariatric surgery.

PTH

Summary: PTH-ELP for hypoparathyroidism / hypocalcemia. A weekly PTH could significantly improve patient adherence, leading to improved outcomes.